$0.88 EPS Expected for Edwards Lifesciences Corp (EW)

July 17, 2017 - By Marguerite Chambers

 $0.88 EPS Expected for Edwards Lifesciences Corp (EW)

Wall Street await Edwards Lifesciences Corp (NYSE:EW) to release earnings on July, 25. Analysts forecast earnings per share of $0.88, up exactly $0.12 or 15.79 % from 2014’s $0.76 EPS. The expected EW’s profit could reach $186.06 million giving the stock 33.05 P/E in the case that $0.88 earnings per share is reported. After posting $0.94 EPS for the previous quarter, Edwards Lifesciences Corp’s analysts now forecast -6.38 % negative EPS growth. About 430,855 shares traded. Edwards Lifesciences Corp (NYSE:EW) has risen 15.41% since July 17, 2016 and is uptrending. It has underperformed by 1.29% the S&P500.

Edwards Lifesciences Corp (NYSE:EW) Ratings Coverage

Among 25 analysts covering Edwards Lifesciences Corp (NYSE:EW), 18 have Buy rating, 1 Sell and 6 Hold. Therefore 72% are positive. Edwards Lifesciences Corp had 65 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Sell” rating on Wednesday, July 27 by Citigroup. The rating was upgraded by Northland Capital on Tuesday, November 8 to “Outperform”. On Wednesday, October 26 the stock rating was maintained by Stifel Nicolaus with “Buy”. As per Wednesday, April 27, the company rating was maintained by Citigroup. The company was initiated on Friday, January 8 by Suntrust Robinson. Barclays Capital maintained the stock with “Equal-Weight” rating in Thursday, April 7 report. The stock of Edwards Lifesciences Corp (NYSE:EW) earned “Market Perform” rating by Northland Capital on Tuesday, April 5. The stock of Edwards Lifesciences Corp (NYSE:EW) earned “Outperform” rating by RBC Capital Markets on Wednesday, April 26. The stock of Edwards Lifesciences Corp (NYSE:EW) earned “Buy” rating by Jefferies on Thursday, June 29. RBC Capital Markets maintained the shares of EW in report on Wednesday, October 26 with “Outperform” rating.

Edwards Lifesciences Corporation is a maker of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The company has market cap of $24.60 billion. The Firm is engaged in patient-focused innovations for structural heart disease and critical care monitoring. It has a 38.51 P/E ratio. The Company’s divisions include United States, Europe, Japan and Rest of World.

More recent Edwards Lifesciences Corp (NYSE:EW) news were published by: Nasdaq.com which released: “Avantor to Acquire VWR, Consolidation Promises Global Gains” on July 14, 2017. Also Fool.com published the news titled: “Here’s What’s Pumping Up Shares of Edwards Lifesciences Corp. Today” on April 26, 2017. Nasdaq.com‘s news article titled: “DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando” with publication date: July 14, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: